Radiation-Fighting Drug

A hydroxylase inhibitor that prolongs the action of a gut-protective protein shows promise in mice as a treatment for radiation poisoning.

Written byRina Shaikh-Lesko
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, NEPHRONA protein that protects the cells that line the gut may be able to prevent gastrointestinal damage following radiation, which can often be fatal, according to a study published this week (May 14) in Science Translational Medicine. A team led by Amato Giaccia of the Stanford University School of Medicine found that in mice a drug called dimethyloxallyl glycine (DMOG), which neutralizes enzymes that reduce levels of this protein, called hypoxia-inducible factor 2 (HIF2), protected against radiation-induced gut damage.

The work was funded by the National Institutes of Health as part of a plan to develop medical interventions for use after a “dirty bomb” is detonated. But Giaccia’s team next plans to develop a version of the drug that can be used to protect healthy cells in people undergoing radiation therapy. Current therapies concentrate radiation narrowly around the target, such as a tumor, but metastasized cancer cells can spread the disease to other parts of the body. With a drug like Giaccia’s to protect gut cells, cancer patients might be able to undergo full-body radiation therapy, perhaps halting the tumor’s spread.

“We’re thinking about using this to transform radiotherapy from a localized type of therapy to a systemic therapy,” Giaccia told Nature News. “The ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies